Telavancin is a semisynthetic, lipoglycopeptide antibiotic. Telavancin exerts
concentration-dependent, bactericidal activity against Gram-positive organisms
in vitro, as demonstrated by time-kill assays and MBC/MIC (minimum bactericidal
concentration/minimum inhibitory concentration) ratios using broth dilution
methodology. In vitro studies demonstrated a telavancin post-antibiotic effect
ranging from 1 to 6 hours against S. aureus and other Gram-positive pathogens.
Although telavancin is approximately 90% protein bound, the presence of human
serum or human serum albumin has minimal impact on the in vitro activity of
telavancin against staphylococci, streptococci, and vancomycin-susceptible
Mechanism of Action:
Telavancin inhibits bacterial cell wall synthesis by interfering with the
polymerization and cross-linking of peptidoglycan. Telavancin binds to the
bacterial membrane and disrupts membrane barrier function.
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used
only to treat infections that are proven or strongly suspected to be caused by
susceptible bacteria. When culture and susceptibility information are available,
they should be considered in selecting or modifying antibacterial therapy. In
the absence of such data, local epidemiology and susceptibility patterns may
contribute to the empiric selection of therapy.
Complicated Skin and Skin Structure Infections:
VIBATIV is indicated for the treatment of adult patients with complicated skin
and skin structure infections (cSSSI) caused by susceptible isolates of the
following Gram-positive microorganisms: Staphylococcus aureus (including
methicillin-susceptible and -resistant isolates), Streptococcus pyogenes,
Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus,
S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible
Combination therapy may be clinically indicated if the documented or presumed
pathogens include Gram-negative organisms.
Appropriate specimens for bacteriological examination should be obtained in
order to isolate and identify the causative pathogens and to determine their
susceptibility to telavancin. VIBATIV may be initiated as empiric therapy before
results of these tests are known.
DOSAGE AND ADMINISTRATION Complicated Skin and Skin Structure Infections:
The recommended dosing for VIBATIV is 10 mg/kg administered over a 60-minute
period in patients 18 years
of age by intravenous infusion once every 24 hours for 7 to 14 days. The
duration of therapy should be guided by the severity and site of the infection
and the patient's clinical and bacteriological progress.
Patients with Renal Impairment:
Because telavancin is eliminated primarily by the kidney, a dosage
adjustment is required for patients whose creatinine clearance is
50 mL/min, as
listed in Table 1:
Table 1: Dosage Adjustment in Adult Patients with Renal
10 - <30 mL/min: 10 mg/kg every 48
* As calculated using the Cockcroft-Gault formula
There is insufficient information to make specific dosage adjustment
recommendations for patients with end-stage renal disease (CrCl <10 mL/min),
including patients undergoing hemodialysis.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read